Navigation Links
RSCI Announces World-Leading Stem Cell Science Advisory Board
Date:5/27/2009

The Repair Stem Cell Institute (RSCI) today announced its 2009 Science Advisory Board. Once again this year, every member of the SAB is a stem cell world-leader and has a world-first to his credit.

Dallas, Texas (PRWEB) May 27, 2009 -- The Repair Stem Cell Institute (RSCI) http://www.RepairStemCells.org, a Dallas, Texas-based stem cell global public affairs organization founded in April 2008, today announced the annual appointments of its Science Advisory Board (SAB) which consists of five of the world's leading Repair (Adult) Stem Cell treatment science and research professionals.

According to Don Margolis, RSCI Chairman, "RSCI's Science Advisory Board carries on our mission of providing the public with the latest Repair Stem Cell (RSC) research and therapeutic innovations. Repair Stem Cells include both autologous (from the patient) and cord blood. There is no organization in the world which can match these five leaders in stem cell treatment accomplishments---none. They actively research and successfully treat patients suffering from heart disease, cancer, diabetes, spinal cord injury, Multiple Sclerosis, ALS, and a dozen other incapacitating conditions with Repair Stem Cells. That covers over 90% of the world's incurable patients."

SAB Chairman Roberto Jorge Fernandez - Viña, M.D. is a world pioneer in developing stem cell therapies for heart diseases, Type 2 Diabetes, and serious lung disorders. He has treated hundreds of patients with stem cells for these conditions, both in his clinic in Argentina and in other clinics in Latin American countries. He proved the great healing benefit of RSC for heart patients in South American clinical trials in 2003-04, and is the first and only person with a successful clinical trial on treating Type 2 Diabetes with stem cells.

Professor Shimon Slavin, M.D., Deputy Chairman, is an expert bone marrow transplantation scientist and clinician, is famous for his innovative clinical application of cell-mediated immunotherapy for the treatment of cancers plus multiple sclerosis and ALS. He is the pioneer for all three. Dr. Slavin is the medical & scientific director of the International Center for Cell Therapy & Cancer (ICTC) at the Tel Aviv (Sourasky) Medical Center in Israel.

SAB Chairman Emeritus Kitipan V. Arom, M.D., Ph.D., FACS, FACC, FACCP, FRCST, established an innovative stem cell treatment program at Bangkok Heart Hospital (BHH) and may be the only doctor in the world to successfully inject stem cells directly into the heart muscles of more than 120 late-stage heart patients. Dr. Kit is the associate professor of surgery and chief cardiothoracic surgeon at BHH. He is a co-founder of the Minneapolis Heart and is the President of the Society of Thoracic Surgeons of Thailand.

Carlos Lima, M.D., one of the foremost neuropathologist experts in stem cell treatments, rejected traditional bone marrow stem cells as a too-limited source for the neurological stem cells required to repair injured spinal cords. Using olfactory stem cells harvested from the patient's own nose, Dr. Lima transplants the cells at the spinal cord break utilizing the successful OMA transplant surgical procedure he developed. He was the first doctor in the world whose treatments, coupled with extensive rehabilitation therapy, created the neurological redevelopment required to allow some paraplegics to rise from their wheelchairs and walk.

Zannos G. Grekos, M.D., F.A.A.C. Director of Cardiology & Vascular Disease, Regenocyte and Clinical Assistant Professor, Nova Southeastern University, is an RSC innovator. Dr. Grekos is the first to inject stem cells into the muscle of the heart via catheterization. This procedure produces significantly less "spillage," maximizing cell utilization at the target region. In May he saved a young cardiomyopathy patient with serious complications by developing a new multi-faceted comprehensive stem cell treatment procedure. Dr. Grekos treats pulmonary hypertension and fibrosis, heart and peripheral vascular diseases, and is the only doctor known to have a successful stem cell therapy for renal problems.

"To summarize," said Mr. Margolis, "these five men have improved the lives of more 'untreatable' patients than all of the world's thousands of embryonic doctors and scientists combined---and that will still be true a decade from now!"

About The Repair Stem Cell Institute: The Repair Stem Cell Institute's mission is to educate and inform everyone about the rapid advances being made in Repair Stem Cell research, so all can intelligently exercise freedom of choice in medical care. If you, or a loved one, is seeking treatment for your "untreatable" medical condition and wish to avoid less competent stem cell clinics, visit http://www.repairstemcells.org for our list of the eight most experienced and successful stem cell treatment centers in the world, as well as the standards applied to them.

###

Read the full story at http://www.prweb.com/releases/2009/05/prweb2458954.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. TED Conferences Announces 25 TED Fellows for TEDGlobal in Oxford
2. Simcere Pharmaceutical Group Announces Agreement to Acquire 37.5% Stake in Jiangsu Yanshen Biological Technology Stock Co., Ltd.
3. Beactica Announces Drug Discovery Agreement With Cubist Pharmaceuticals
4. Transgenomic, Inc. Announces Appointment of New Board Members
5. Johnson & Johnson Announces Definitive Agreement to Acquire Cougar Biotechnology, Inc.
6. American Acne & Rosacea Society Announces Acne Awareness Month - June 2009
7. Cephalon Announces Proposed Public Offering of Common Stock and Convertible Senior Subordinated Notes
8. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
9. Aesthera Announces ANVISA Clearance to Market Photopneumatic Platforms in Brazil
10. Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing
11. Beckman Coulter, Inc. Announces Pricing of Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
RSCI Announces World-Leading Stem Cell Science Advisory Board
(Date:6/23/2016)... , June 23, 2016 A person commits a ... crime scene to track the criminal down. An ... Food and Drug Administration (FDA) uses DNA evidence to track ... Sound far-fetched? It,s not. The FDA has increasingly ... support investigations of foodborne illnesses. Put as simply as possible, ...
(Date:6/23/2016)... Lawrence, MA (PRWEB) , ... June 23, 2016 ... ... the Peel Plate® YM (Yeast and Mold) microbial test has received AOAC Research ... test platform of microbial tests introduced last year,” stated Bob Salter, Vice President ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
Breaking Biology Technology:
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... when it comes to expanding freedom for high net ... Even in today,s globally connected world, there is ... conferencing system could ever duplicate sealing your deal with ... obtaining second passports by taking advantage of citizenship via ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
Breaking Biology News(10 mins):